Though current findings exclude a role of hepatocyte produced muChem-156 herein, injection of active chemerin isoforms may nevertheless improve NAFLD pathology by reducing body weight [25]. The gene discussed is RARRES2; the disease is metabolic dysfunction-associated steatotic liver disease.